ATE355055T1 - Pharmazeutische zusammensetzung enthaltend einen ltb4-hemmer sowie einen cox-2-hemmer oder einen kombinierten cox1/2-hemmer - Google Patents
Pharmazeutische zusammensetzung enthaltend einen ltb4-hemmer sowie einen cox-2-hemmer oder einen kombinierten cox1/2-hemmerInfo
- Publication number
- ATE355055T1 ATE355055T1 AT03795825T AT03795825T ATE355055T1 AT E355055 T1 ATE355055 T1 AT E355055T1 AT 03795825 T AT03795825 T AT 03795825T AT 03795825 T AT03795825 T AT 03795825T AT E355055 T1 ATE355055 T1 AT E355055T1
- Authority
- AT
- Austria
- Prior art keywords
- inhibitor
- cox1
- pharmaceutically acceptable
- ltb4
- combined
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 101150031809 cox1/2 gene Proteins 0.000 title abstract 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940111134 coxibs Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical group NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026223 | 2002-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE355055T1 true ATE355055T1 (de) | 2006-03-15 |
Family
ID=32337995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03795825T ATE355055T1 (de) | 2002-11-26 | 2003-11-18 | Pharmazeutische zusammensetzung enthaltend einen ltb4-hemmer sowie einen cox-2-hemmer oder einen kombinierten cox1/2-hemmer |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040116516A1 (de) |
| EP (1) | EP1572179B1 (de) |
| JP (1) | JP2006508992A (de) |
| KR (1) | KR20050086820A (de) |
| CN (1) | CN1717228A (de) |
| AT (1) | ATE355055T1 (de) |
| AU (1) | AU2003298121A1 (de) |
| BR (1) | BR0316486A (de) |
| CA (1) | CA2506948A1 (de) |
| CO (1) | CO5580753A2 (de) |
| DE (1) | DE60312215T2 (de) |
| EA (1) | EA200500860A1 (de) |
| EC (1) | ECSP055804A (de) |
| ES (1) | ES2282727T3 (de) |
| HR (1) | HRP20050466A2 (de) |
| MX (1) | MXPA05005393A (de) |
| PE (1) | PE20040697A1 (de) |
| PL (1) | PL375503A1 (de) |
| RS (1) | RS20050390A (de) |
| TW (1) | TW200500330A (de) |
| UY (1) | UY28095A1 (de) |
| WO (1) | WO2004047824A1 (de) |
| ZA (1) | ZA200502410B (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0508063A (pt) * | 2004-06-29 | 2007-07-17 | Nycomed Danmark Aps | processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica |
| EP3623368A4 (de) | 2017-05-12 | 2021-04-07 | Riken | Modifikator einer verbindung mit klasse-a-gpcr-bindung |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4424713A1 (de) * | 1994-07-13 | 1996-01-18 | Boehringer Ingelheim Kg | Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe |
| US6342510B1 (en) * | 1995-06-12 | 2002-01-29 | G. D. Searle & Co. | Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist |
| DE19546452A1 (de) * | 1995-12-13 | 1997-06-19 | Boehringer Ingelheim Kg | Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel |
| ES2243978T3 (es) * | 1996-02-13 | 2005-12-01 | G.D. SEARLE & CO. | Composiciones que comprenden un inhibidor de la ciclooxigenasa-2 y un antagonista del receptor de leucotrieno b4. |
| DE19636689A1 (de) * | 1996-09-10 | 1998-03-12 | Boehringer Ingelheim Kg | Neue Benzamidinderivate |
| US6197753B1 (en) * | 1997-09-10 | 2001-03-06 | Boehringer Ingelheim Kg | Pyranoside derivatives |
| US6291531B1 (en) * | 1999-10-07 | 2001-09-18 | Boehringer Ingelheim Pharma Kg | LTB4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition |
| US6417382B2 (en) * | 2000-01-12 | 2002-07-09 | Boehringer Ingelheim Pharma Kg | Process for preparing aryl-iminomethyl-carbamino acid esters |
| AR030382A1 (es) * | 2000-08-18 | 2003-08-20 | Yamanouchi Pharma Tech Inc | Formulacion oral de un inhibidor de ciclooxigenasa-2 de fusion rapida |
| WO2002055065A2 (en) * | 2001-01-16 | 2002-07-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| WO2003007922A2 (de) * | 2001-07-14 | 2003-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Arzneimittelformulierung enthaltend einen ltb4 antagonisten |
| US20030119901A1 (en) * | 2001-07-14 | 2003-06-26 | Boehringer Ingelheim Pharma Kg | Pharmaceutical formulation containing an LTB4 antagonist |
-
2003
- 2003-10-25 RS YUP-2005/0390A patent/RS20050390A/sr unknown
- 2003-11-18 MX MXPA05005393A patent/MXPA05005393A/es unknown
- 2003-11-18 HR HR20050466A patent/HRP20050466A2/xx not_active Application Discontinuation
- 2003-11-18 DE DE60312215T patent/DE60312215T2/de not_active Expired - Fee Related
- 2003-11-18 AU AU2003298121A patent/AU2003298121A1/en not_active Abandoned
- 2003-11-18 CA CA002506948A patent/CA2506948A1/en not_active Abandoned
- 2003-11-18 ES ES03795825T patent/ES2282727T3/es not_active Expired - Lifetime
- 2003-11-18 BR BR0316486-1A patent/BR0316486A/pt not_active IP Right Cessation
- 2003-11-18 CN CNA2003801042779A patent/CN1717228A/zh active Pending
- 2003-11-18 PL PL03375503A patent/PL375503A1/xx unknown
- 2003-11-18 AT AT03795825T patent/ATE355055T1/de not_active IP Right Cessation
- 2003-11-18 EA EA200500860A patent/EA200500860A1/ru unknown
- 2003-11-18 JP JP2004554378A patent/JP2006508992A/ja active Pending
- 2003-11-18 WO PCT/EP2003/012874 patent/WO2004047824A1/en not_active Ceased
- 2003-11-18 KR KR1020057009428A patent/KR20050086820A/ko not_active Withdrawn
- 2003-11-18 EP EP03795825A patent/EP1572179B1/de not_active Expired - Lifetime
- 2003-11-21 US US10/719,125 patent/US20040116516A1/en not_active Abandoned
- 2003-11-24 TW TW092132937A patent/TW200500330A/zh unknown
- 2003-11-24 PE PE2003001187A patent/PE20040697A1/es not_active Application Discontinuation
- 2003-11-26 UY UY28095A patent/UY28095A1/es not_active Application Discontinuation
-
2005
- 2005-03-23 ZA ZA200502410A patent/ZA200502410B/en unknown
- 2005-05-19 EC EC2005005804A patent/ECSP055804A/es unknown
- 2005-06-24 CO CO05062367A patent/CO5580753A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1572179A1 (de) | 2005-09-14 |
| DE60312215D1 (de) | 2007-04-12 |
| ECSP055804A (es) | 2005-08-11 |
| HRP20050466A2 (en) | 2006-07-31 |
| CO5580753A2 (es) | 2005-11-30 |
| EA200500860A1 (ru) | 2005-12-29 |
| EP1572179B1 (de) | 2007-02-28 |
| JP2006508992A (ja) | 2006-03-16 |
| PL375503A1 (en) | 2005-11-28 |
| US20040116516A1 (en) | 2004-06-17 |
| BR0316486A (pt) | 2005-10-11 |
| AU2003298121A1 (en) | 2004-06-18 |
| MXPA05005393A (es) | 2005-08-03 |
| ZA200502410B (en) | 2005-10-03 |
| PE20040697A1 (es) | 2004-11-22 |
| KR20050086820A (ko) | 2005-08-30 |
| TW200500330A (en) | 2005-01-01 |
| ES2282727T3 (es) | 2007-10-16 |
| UY28095A1 (es) | 2004-06-30 |
| WO2004047824A1 (en) | 2004-06-10 |
| DE60312215T2 (de) | 2007-06-28 |
| RS20050390A (sr) | 2008-04-04 |
| CN1717228A (zh) | 2006-01-04 |
| CA2506948A1 (en) | 2004-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| NO20042161L (no) | Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1 | |
| MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
| SE0001899D0 (sv) | New compounds | |
| NO20062504L (no) | Sammensetninger og doseringsformer for forbedret absorpsjon | |
| TW200736223A (en) | N-(pyridin-2-yl)-sulfonamide derivatives | |
| HRP20040996B1 (hr) | Tablete visokog sadržaja lijeka | |
| IL165264A (en) | Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases | |
| SE0300010D0 (sv) | Novel Compounds | |
| SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
| SE0401342D0 (sv) | Therapeutic compounds | |
| SE9900961D0 (sv) | Novel compounds | |
| UA86776C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение | |
| SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
| CY1107819T1 (el) | Φαρμακευτικη διαμορφωση της ολανζαπινης | |
| TW200504029A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| UA83832C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение | |
| WO2005075471A3 (en) | Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors | |
| ECSP066878A (es) | [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa | |
| SE0302570D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| SE0302572D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| MY139613A (en) | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders | |
| DE60312215D1 (de) | Pharmazeutische zusammensetzung enthaltend einen ltb4-hemmer sowie einen cox-2-hemmer oder einen kombinierten cox1/2-hemmer | |
| WO2005035500A3 (en) | Therapeutic agents useful for treating pain | |
| SE0301698D0 (sv) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1572179 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |